It’s Official: FDA Approval Does Not Equal CMS Coverage
This article was originally published in RPM Report
Medicare’s updated coverage determination policy spells out in black-and-white that the payor agency does not feel that the law requires it to pay for FDA-approved products used on-label.
You may also be interested in...
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
The long-talked about wave of gene therapy approvals is beginning to reveal itself.
A case involving a tax that was an “exceedingly heavy burden” and played into the Supreme Court’s original ruling on the ACA could reemerge once the IRA challenge reaches the high court.